โ
๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข Product Sales: $8.3B (+13% YoY)
โข Product Sales Excluding Veklury: $8.2B (+16% YoY)
โข GAAP EPS: $1.94 vs. $2.43 YoY
โข Non-GAAP EPS: $2.55 vs. $2.47 YoY
โข GAAP Product Gross Margin: 81.0% vs. 78.6% YoY
โข Non-GAAP Product Gross Margin: 88.1% vs. 86.5% YoY
โข Operating Cash Flow: $5.0B
โ
๐ฏ ๐๐ฎ๐ข๐๐๐ง๐๐ (๐ ๐๐๐)
โข Product Sales: $31.0Bโ$31.3B (prior $30.1Bโ$30.4B)
โข Product Sales Excluding Veklury: $30.7Bโ$31.0B (prior $29.8Bโ$30.1B)
โข GAAP EPS: -$4.40 to -$4.05 (prior -$3.75 to -$3.40)
โข Non-GAAP EPS: -$1.20 to -$0.85 (prior -$0.65 to -$0.30)
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข HIV revenue +18% to $6.2B; HIV prevention sales nearly doubled YoY
โข Biktarvy +10% to $4.1B; Descovy +49% to $1.0B
โข Trodelvy revenue +42% to $506M; Cell Therapy revenue -18% to $355M
โข Liver Disease portfolio +13% to $927M; Veklury -69% to $86M
โข FY26 EPS outlook includes ~$12.4B in acquired IPR&D charges, equivalent to a ~$9.88/share impact
โข FDA approved Bixlenvo for virologically suppressed adults with HIV
โข EU approved Trodelvy + Keytruda for first-line metastatic triple-negative breast cancer in eligible patients
โข Positive Phase 2 emvistegrast data in ulcerative colitis; Phase 3 planned for 2027
โข Cash & Marketable Securities: $6.4B
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐จ๐ฆ๐ฆ๐๐ง๐ญ๐๐ซ๐ฒ
โGilead delivered an exceptional third quarter, with our strongest year-over-year base business growth in more than a decade, reflecting the strength, breadth and durability of our business.โ โ CEO Daniel OโDay